Novavax Inc. is a Novavax Inc is a biotechnology company that develops vaccines. The company is in the clinical development phase with a focus on delivering novel products that prevent a wide range of diseases.
Novavax Inc. (NVAX) had a difficult trading day on Tuesday, March 23rd
fell 7.32%, or a loss of $ 17.36 per share, to close at $ 219.84. After opening the day at $ 237.50, Novavax Inc. shares traded at $ 239.54 and up to $ 239.54
as low as $ 218.61. The volume was 2 million shares over 38,195 trades, compared to an average daily volume of 100,000 shares and a total float of 73.86 million.
As a result of the decline, Novavax Inc. now has a market capitalization of $ 16.24 billion. In the last
Novavax Inc. shares traded between $ 331.68 and $ 10.03 for the year. The 50-day SMA is currently n / a and the 200-day SMA is n / a.
For complete fundamental research from Novavax Inc., see Equities.com’s Stock Valuation Analysis report for
Do you still pay commissions on stock trades? Equities.com now offers unlimited trading for $ 7.99 / month and flat rate options for $ 89.99 / month! Get started today at https://www.equities.com/trading-start
Novavax Inc is a biotechnology company that develops vaccines. The company is in the clinical development phase with a focus on delivering novel products that prevent a wide range of diseases. Novavax is working with its wholly-owned Swedish subsidiary to develop vaccine candidates that respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied to a wide variety of infectious diseases in humans. Novavax develops product candidates that target all age groups of the general population.
Novavax Inc. is based in Gaithersburg, MD and has approximately 791 employees. Its CEO is Stanley Charles Erck.
Novavax Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices for small-cap companies in the USA. It is made by Russell Investments, a
Industry leader in index creation and maintenance and is comprised of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices such as the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by the committee because they focus solely on one
objective, rule-based methodology. The 3,000 largest companies by market capitalization make up the Russell 3000, and the 2,000 smaller companies make up the Russell 2000. This is a simple approach
A broad, unbiased look at the small cap market as a whole.
For more information on Novavax Inc. and the latest updates from the company, please visit the company’s profile page here:
NVAX profile. For more information on the financial markets and emerging growth companies, visit Equities.com
News desk. Also, don’t forget to sign up for our daily registration
Email newsletters to make sure you don’t miss any of our best stories.
The views and opinions expressed in this article are those of the authors and do not reflect those of equities.com. Readers should not regard statements made by the author as a formal recommendation and should consult their financial advisor prior to making any investment decisions. Our full disclosure is available at: http://www.equities.com/disclaimer
I’m sorry, but you need to be signed in to be able to complete what you’re trying to do.
Related Title :
– <a href = "/? s = Can Novavax Inc. (NASDAQ: NVAX) Offer Investors Security? NASDAQ: NVAX) Are you bidding Investor security?
– <a href = "/? S = NVAX Stock – Approval of the vaccines CureVac, Sputnik and Novavax by the European Medicines Agency CureVac, Sputnik and Novavax vaccines by the European Medicines Agency Agency
– Novavax Inc. (NVAX) down 7.32% on March 23
Donnez votre avis et abonnez-vous pour plus d’infos
Vidéo du jour: